Get the Stockscreener App
1.13
8.87%
-0.11
Pre-market:
1.13
Biodesix Inc stock is traded at $1.13, with a volume of 473.96K.
It is down -8.87% in the last 24 hours and down -15.67% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
See More
Previous Close:
$1.24
Open:
$1.25
24h Volume:
473.96K
Relative Volume:
1.12
Market Cap:
$164.38M
Revenue:
$49.09M
Net Income/Loss:
$-52.15M
P/E Ratio:
-1.7385
EPS:
-0.65
Net Cash Flow:
$-45.93M
1W Performance:
-24.16%
1M Performance:
-15.67%
6M Performance:
-33.14%
1Y Performance:
-42.64%
1-Day Range:
$1.13
$1.26
1-Week Range:
$1.13
$1.5109
52-Week Range:
$1.11
$2.21
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
1.13 | 164.38M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
556.99 | 213.05B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
237.62 | 171.63B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
143.43 | 40.54B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.96 | 35.93B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
418.63 | 34.28B | 3.84B | 866.24M | 792.60M | 10.37 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test - MSN
Biodesix, Inc. (NASDAQ:BDSX) Shares Bought by Barclays PLC - Defense World
Preliminary results show sales boost for Biodesix - BizWest
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited) - GlobeNewswire
Biodesix Achieves Record 45% Revenue Growth to $71.3M as Lung Diagnostics Surges in 2024 - StockTitan
Geode Capital Management LLC Has $1.43 Million Stock Position in Biodesix, Inc. (NASDAQ:BDSX) - Defense World
Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study - The Manila Times
Biodesix's Lung Cancer Blood Test Outperforms PET Scans in Major Clinical Study - StockTitan
Biodesix, Inc. (NASDAQ:BDSX) Q3 2024 Earnings Call Transcript - MSN
Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Expands By 44.7% - MarketBeat
Contrasting Biodesix (NASDAQ:BDSX) & MDxHealth (NASDAQ:MDXH) - Defense World
Wilmington Savings Fund Society FSB Takes Position in Biodesix, Inc. (NASDAQ:BDSX) - MarketBeat
Best Project, Interior/Tenant: Biodesix Corporate Headquarters and Laboratory - Engineering News-Record
Insider Buys Additional US$234k In Biodesix Stock - Yahoo Finance
Biodesix director Jack Schuler buys $122,840 in stock By Investing.com - Investing.com Canada
Biodesix director Kennedy Lawrence T. Jr buys $40,561 in stock - Investing.com India
Biodesix director Kennedy Lawrence T. Jr buys $40,561 in stock By Investing.com - Investing.com Canada
Biodesix director Jack Schuler buys $122,840 in stock - Investing.com
Biodesix Inc director Jack Schuler buys $234,000 in shares - Investing.com India
Biodesix Inc director Jack Schuler buys $234,000 in shares By Investing.com - Investing.com UK
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For - Simply Wall St
Biodesix Reports Strong Q3 2024 Growth in Diagnostics - MSN
Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Biodesix chief commercial officer sells shares worth $644 By Investing.com - Investing.com Australia
Biodesix chief commercial officer sells shares worth $644 - Investing.com India
Biodesix CEO Scott Hutton sells $5,219 in stock - Investing.com India
Biodesix CEO Scott Hutton sells $5,219 in stock By Investing.com - Investing.com Australia
Biodesix CFO Robin Harper Cowie sells $1,355 in stock By Investing.com - Investing.com Australia
Biodesix CFO Robin Harper Cowie sells $1,355 in stock - Investing.com
Biodesix chief accounting officer sells $283 in stock - Investing.com
Insider Buys Additional US$137k In Biodesix Stock - Simply Wall St
Biodesix chairman John Patience acquires $103,710 in stock - Investing.com India
Biodesix chairman John Patience acquires $103,710 in stock By Investing.com - Investing.com Australia
Biodesix director Jack Schuler buys $136k in stock - Investing.com
Biodesix director Kennedy Lawrence T. Jr. acquires $97,068 in stock - Investing.com
Biodesix director Matthew Strobeck acquires $55,915 in stock - Investing.com
Biodesix director Massarany buys $30,865 in common stock - Investing.com India
Biodesix director Kennedy Lawrence T. Jr. acquires $97,068 in stock By Investing.com - Investing.com Nigeria
Earnings call: Biodesix sees strong growth in Q3 with $18.2M revenue - Investing.com India
Brokerages Set Biodesix, Inc. (NASDAQ:BDSX) PT at $3.06 - MarketBeat
Biodesix, Inc. (NASDAQ:BDSX) Receives Consensus Rating of “Buy” from Analysts - Defense World
Biodesix (NASDAQ:BDSX) Releases Quarterly Earnings Results, Meets Expectations - MarketBeat
Biodesix reports Q3 EPS (7c), consensus (7c) - MSN
Biodesix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.17%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):